FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3209945487> ?p ?o ?g. }

• W3209945487 endingPage "e276" @default.
• W3209945487 startingPage "e275" @default.
• W3209945487 abstract "Purpose/Objective(s)Stereotactic Body Radiation Therapy (SBRT) is a standard therapeutic option for men with prostate adenocarcinoma. The median age of prostate cancer in the US is 66 but patients as young as 35 have been reported. Many younger patients will have surgery rather than SBRT for localized prostate cancer but some will be treated with SBRT. There is a paucity of data on the outcomes of this younger subset. This study reports outcomes on patients younger than 50 treated with SBRT at a single institution and compares outcomes to older patients.Materials/MethodsBetween April 2006 and December 2020, 3626 patients with prostate cancer were treated with inhomogeneous-dosed SBRT using a robotic linear accelerator and followed at an academic institution. 3173 (87.51%) of patients were treated with a median dose of 3500cGY (3500-3625) delivered over 5 consecutive fractions prescribed to the 83-85% isodose line, and the remaining 453 (12.49%) other patients receiving a median dose of 4500cGY (4500-5400) to the pelvis in conventional fractionation followed by a 3 fraction SBRT boost of 2100 cGY (1950-2100) over 3 consecutive fractions. Androgen deprivation Therapy (ADT) was prescribed in 865 (23.86%) of these cases. The mean age was 67.3 years old. 47 patients were younger than 50 years old (mean age 46.6). 3,579 patients were 50 or older. Patients were divided into prognostic D'Amico risk groups with 44.68%, 48.94%, 6.38% of patients falling in the low, intermediate, and high-risk stratifications in the younger cohort and 24.76%, 56.83%, 18.41% in the older cohort respectively. Pretreatment PSA was 1.72 - 43.2 (median: 5.4) in the younger group and 0.3 - 661 (median: 6.5) in the older group. In the younger group, Gleason scores were 6 in 48.94%, 7 in 46.81%, and 8-10 in 4.25%. 44 younger patients were treated with SBRT alone. 3 patients also received supplemental external beam radiation (median dose 4500cGY) and 5 patients (10.6%) received Androgen Deprivation Therapy (ADT) as part of their treatment regimen. In the older group, Gleason scores were 6 in 30.57%, 7 in 54.06%, and 8-10 in 15.37%. 3129 were treated with SBRT alone. 450 patients also received supplemental external beam radiation (median dose 4500cGY) and 860 patients (24.03%) received Androgen Deprivation Therapy (ADT) as part of their treatment regimen.ResultsAt 64.8 months (range 7 months - 177 months) the 5-year biochemical relapse free survival was 98% in younger patients compared to 99% in older patients using the Phoenix definition of biochemical failure. The 5-year median post treatment PSA was 0.15 in the younger patients and 0.20 in the older patients. There were no significant differences in biochemical relapse free survival between the groups.ConclusionThis represents the largest series evaluating outcomes in very young patients treated with definitive SBRT for prostate cancer. With 5-year follow up, SBRT is an effective treatment for this younger subset of patients. Continued follow up will be required to see if these results remain durable. Stereotactic Body Radiation Therapy (SBRT) is a standard therapeutic option for men with prostate adenocarcinoma. The median age of prostate cancer in the US is 66 but patients as young as 35 have been reported. Many younger patients will have surgery rather than SBRT for localized prostate cancer but some will be treated with SBRT. There is a paucity of data on the outcomes of this younger subset. This study reports outcomes on patients younger than 50 treated with SBRT at a single institution and compares outcomes to older patients. Between April 2006 and December 2020, 3626 patients with prostate cancer were treated with inhomogeneous-dosed SBRT using a robotic linear accelerator and followed at an academic institution. 3173 (87.51%) of patients were treated with a median dose of 3500cGY (3500-3625) delivered over 5 consecutive fractions prescribed to the 83-85% isodose line, and the remaining 453 (12.49%) other patients receiving a median dose of 4500cGY (4500-5400) to the pelvis in conventional fractionation followed by a 3 fraction SBRT boost of 2100 cGY (1950-2100) over 3 consecutive fractions. Androgen deprivation Therapy (ADT) was prescribed in 865 (23.86%) of these cases. The mean age was 67.3 years old. 47 patients were younger than 50 years old (mean age 46.6). 3,579 patients were 50 or older. Patients were divided into prognostic D'Amico risk groups with 44.68%, 48.94%, 6.38% of patients falling in the low, intermediate, and high-risk stratifications in the younger cohort and 24.76%, 56.83%, 18.41% in the older cohort respectively. Pretreatment PSA was 1.72 - 43.2 (median: 5.4) in the younger group and 0.3 - 661 (median: 6.5) in the older group. In the younger group, Gleason scores were 6 in 48.94%, 7 in 46.81%, and 8-10 in 4.25%. 44 younger patients were treated with SBRT alone. 3 patients also received supplemental external beam radiation (median dose 4500cGY) and 5 patients (10.6%) received Androgen Deprivation Therapy (ADT) as part of their treatment regimen. In the older group, Gleason scores were 6 in 30.57%, 7 in 54.06%, and 8-10 in 15.37%. 3129 were treated with SBRT alone. 450 patients also received supplemental external beam radiation (median dose 4500cGY) and 860 patients (24.03%) received Androgen Deprivation Therapy (ADT) as part of their treatment regimen. At 64.8 months (range 7 months - 177 months) the 5-year biochemical relapse free survival was 98% in younger patients compared to 99% in older patients using the Phoenix definition of biochemical failure. The 5-year median post treatment PSA was 0.15 in the younger patients and 0.20 in the older patients. There were no significant differences in biochemical relapse free survival between the groups. This represents the largest series evaluating outcomes in very young patients treated with definitive SBRT for prostate cancer. With 5-year follow up, SBRT is an effective treatment for this younger subset of patients. Continued follow up will be required to see if these results remain durable." @default.
• W3209945487 created "2021-11-08" @default.
• W3209945487 creator A5000572625 @default.
• W3209945487 creator A5008650462 @default.
• W3209945487 creator A5009937137 @default.
• W3209945487 creator A5033290639 @default.
• W3209945487 creator A5040002880 @default.
• W3209945487 creator A5048314532 @default.
• W3209945487 creator A5056235015 @default.
• W3209945487 creator A5059954903 @default.
• W3209945487 creator A5070438052 @default.
• W3209945487 creator A5071831524 @default.
• W3209945487 creator A5082915859 @default.
• W3209945487 date "2021-11-01" @default.
• W3209945487 modified "2023-09-27" @default.
• W3209945487 title "Robotic SBRT in Prostate Cancer Patients Younger Than 50 Years Old" @default.
• W3209945487 doi "https://doi.org/10.1016/j.ijrobp.2021.07.891" @default.
• W3209945487 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34701071" @default.
• W3209945487 hasPublicationYear "2021" @default.
• W3209945487 type Work @default.
• W3209945487 sameAs 3209945487 @default.
• W3209945487 citedByCount "0" @default.
• W3209945487 crossrefType "journal-article" @default.
• W3209945487 hasAuthorship W3209945487A5000572625 @default.
• W3209945487 hasAuthorship W3209945487A5008650462 @default.
• W3209945487 hasAuthorship W3209945487A5009937137 @default.
• W3209945487 hasAuthorship W3209945487A5033290639 @default.
• W3209945487 hasAuthorship W3209945487A5040002880 @default.
• W3209945487 hasAuthorship W3209945487A5048314532 @default.
• W3209945487 hasAuthorship W3209945487A5056235015 @default.
• W3209945487 hasAuthorship W3209945487A5059954903 @default.
• W3209945487 hasAuthorship W3209945487A5070438052 @default.
• W3209945487 hasAuthorship W3209945487A5071831524 @default.
• W3209945487 hasAuthorship W3209945487A5082915859 @default.
• W3209945487 hasBestOaLocation W32099454871 @default.
• W3209945487 hasConcept C121608353 @default.
• W3209945487 hasConcept C126322002 @default.
• W3209945487 hasConcept C126894567 @default.
• W3209945487 hasConcept C141071460 @default.
• W3209945487 hasConcept C155806632 @default.
• W3209945487 hasConcept C167135981 @default.
• W3209945487 hasConcept C2776235491 @default.
• W3209945487 hasConcept C2776651944 @default.
• W3209945487 hasConcept C2777899217 @default.
• W3209945487 hasConcept C2778357063 @default.
• W3209945487 hasConcept C2780192828 @default.
• W3209945487 hasConcept C2780387249 @default.
• W3209945487 hasConcept C2989005 @default.
• W3209945487 hasConcept C509974204 @default.
• W3209945487 hasConcept C71924100 @default.
• W3209945487 hasConceptScore W3209945487C121608353 @default.
• W3209945487 hasConceptScore W3209945487C126322002 @default.
• W3209945487 hasConceptScore W3209945487C126894567 @default.
• W3209945487 hasConceptScore W3209945487C141071460 @default.
• W3209945487 hasConceptScore W3209945487C155806632 @default.
• W3209945487 hasConceptScore W3209945487C167135981 @default.
• W3209945487 hasConceptScore W3209945487C2776235491 @default.
• W3209945487 hasConceptScore W3209945487C2776651944 @default.
• W3209945487 hasConceptScore W3209945487C2777899217 @default.
• W3209945487 hasConceptScore W3209945487C2778357063 @default.
• W3209945487 hasConceptScore W3209945487C2780192828 @default.
• W3209945487 hasConceptScore W3209945487C2780387249 @default.
• W3209945487 hasConceptScore W3209945487C2989005 @default.
• W3209945487 hasConceptScore W3209945487C509974204 @default.
• W3209945487 hasConceptScore W3209945487C71924100 @default.
• W3209945487 hasIssue "3" @default.
• W3209945487 hasLocation W32099454871 @default.
• W3209945487 hasLocation W32099454872 @default.
• W3209945487 hasOpenAccess W3209945487 @default.
• W3209945487 hasPrimaryLocation W32099454871 @default.
• W3209945487 hasRelatedWork W1982508997 @default.
• W3209945487 hasRelatedWork W2127440557 @default.
• W3209945487 hasRelatedWork W2136389912 @default.
• W3209945487 hasRelatedWork W2282764642 @default.
• W3209945487 hasRelatedWork W2969214722 @default.
• W3209945487 hasRelatedWork W4220991042 @default.
• W3209945487 hasRelatedWork W4286561766 @default.
• W3209945487 hasRelatedWork W4308148977 @default.
• W3209945487 hasRelatedWork W4308663128 @default.
• W3209945487 hasRelatedWork W83392053 @default.
• W3209945487 hasVolume "111" @default.
• W3209945487 isParatext "false" @default.
• W3209945487 isRetracted "false" @default.
• W3209945487 magId "3209945487" @default.
• W3209945487 workType "article" @default.